title: Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization.
abstract: Nanoparticles (NPs) were widely used in drugs/probes delivery for improved disease diagnosis and/or treatment. Targeted delivery to cancer cells is a highly attractive application of NPs. However, few studies have been performed on the targeting mechanisms of these ligand-modified delivery systems. Additional studies are needed to understand the transport of nanoparticles in the cancer site, the interactions between nanoparticles and cancer cells, the intracellular trafficking of nanoparticles within the cancer cells and the subcellular destiny and potential toxicity. Interleukin 13 (IL-13) peptide can specifically bind IL-13Rα2, a receptor that is highly expressed on glioma cells but is expressed at low levels on other normal cells. It was shown that the nanoparticels modification with the IL-13 peptide could improve glioma treatment by selectively increasing cellular uptake, facilitating cell internalization, altering the uptake pathway and increasing glioma localization.
authors: Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education; School of Pharmacy, Fudan University; 826 Zhangheng Road, Shanghai, 201203, China.
authors: Huile
authors: H
authors: Gao
authors: Zhi
authors: Z
authors: Yang
authors: Shuang
authors: S
authors: Zhang
authors: Shijie
authors: S
authors: Cao
authors: Shun
authors: S
authors: Shen
authors: Zhiqing
authors: Z
authors: Pang
authors: Xinguo
authors: X
authors: Jiang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D000077143:Docetaxel; D004705:Endocytosis; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D018793:Interleukin-13 / Q000737:chemistry / Q000493:pharmacokinetics*; D051379:Mice; D008819:Mice, Nude; D053769:Nanocapsules / Q000008:administration & dosage* / Q000737:chemistry; D043823:Taxoids / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018793:Interleukin-13; D053769:Nanocapsules; D043823:Taxoids; D000077143:Docetaxel
references: J Control Release. 2011 Jul 30;153(2):141-8
references: 21447361
references: Mol Pharm. 2010 Dec 6;7(6):1995-2005
references: 20957995
references: Acc Chem Res. 2011 Oct 18;44(10):1123-34
references: 21692448
references: Nanomedicine (Lond). 2011 Apr;6(3):449-58
references: 21542684
references: Biomaterials. 2012 Jul;33(20):5115-23
references: 22484043
references: J Am Chem Soc. 2010 Apr 14;132(14):4980-1
references: 20307100
references: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references: 2946403
references: Biomaterials. 2012 Nov;33(32):8167-76
references: 22889488
references: Biomaterials. 2013 Jan;34(1):196-208
references: 23069707
references: Nat Mater. 2011 May;10(5):389-97
references: 21499315
references: J Control Release. 2010 Apr 2;143(1):136-42
references: 20056123
references: Cancer Res. 2006 Jul 1;66(13):6732-40
references: 16818648
references: Biomaterials. 2011 Nov;32(31):8010-20
references: 21788069
references: Chem Rev. 2011 May 11;111(5):3407-32
references: 21401073
references: ACS Nano. 2012 Jan 24;6(1):410-20
references: 22148835
references: Neoplasia. 2002 Sep-Oct;4(5):388-99
references: 12192597
references: Nat Mater. 2009 Jul;8(7):543-57
references: 19525947
references: Traffic. 2011 Apr;12(4):507-20
references: 21226813
references: J Control Release. 2009 May 5;135(3):259-67
references: 19331853
references: Biomaterials. 2012 Apr;33(11):3324-33
references: 22281423
references: Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1235-40
references: 20080552
references: Biomaterials. 2013 Mar;34(8):2117-29
references: 23245924
references: J Control Release. 2011 Aug 10;153(3):198-205
references: 21663778
references: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):149-68
references: 11259838
references: Biomaterials. 2011 Jun;32(18):4293-305
references: 21427009
references: Biomaterials. 2012 Jan;33(3):916-24
references: 22048008
references: Dev Cell. 2012 Sep 11;23(3):519-32
references: 22940114
references: Int J Pharm. 2011 Aug 30;415(1-2):284-92
references: 21651966
references: Expert Opin Drug Deliv. 2012 Jun;9(6):671-86
references: 22607535
references: J Control Release. 2008 Jun 4;128(2):120-7
references: 18436327
references: Trends Biotechnol. 2008 Oct;26(10):552-8
references: 18722682
references: Biomaterials. 2012 Apr;33(10):2952-60
references: 22245558
references: J Am Chem Soc. 2013 Mar 27;135(12):4799-804
references: 23495667
references: Mol Cancer Ther. 2006 Jul;5(7):1744-53
references: 16891460
references: Oncol Res. 2001;12(11-12):459-67
references: 11939409
references: Nano Lett. 2012 Jul 11;12(7):3417-23
references: 22632479
references: Expert Rev Mol Med. 2011 May 13;13:e17
references: 21676290
references: J Control Release. 2012 Dec 10;164(2):115-24
references: 22484196
references: Biol Res Nurs. 2003 Oct;5(2):117-28
references: 14531216
references: Exp Cell Res. 2013 Feb 1;319(3):32-45
references: 23127513
references: Mol Biol Cell. 2006 Sep;17(9):4105-17
references: 16837554
references: J Biol Chem. 2004 Apr 16;279(16):16657-61
references: 14985334
references: Cancer Res. 2006 Dec 15;66(24):11878-87
references: 17178885